📊 XRAY Key Takeaways
Is DENTSPLY SIRONA Inc. (XRAY) a Good Investment?
DENTSPLY SIRONA faces severe profitability challenges with operating losses of $422M and net losses of $598M despite solid 50% gross margins, indicating structural operational cost issues. Declining revenue (-3.0% YoY) combined with elevated leverage (1.7x Debt/Equity) and negative interest coverage (-23.4x) creates significant financial stress, though positive operating cash flow of $235M and improving EPS trends suggest stabilization efforts are underway.
Why Buy DENTSPLY SIRONA Inc. Stock? XRAY Key Strengths
- Healthy gross margin of 50% indicates pricing power and manufacturing efficiency in core business
- Positive operating cash flow of $235M despite net losses suggests cash generation capability and working capital management
- Improving EPS trend with 33% YoY improvement from negative base indicates management actions taking effect
XRAY Stock Risks: DENTSPLY SIRONA Inc. Investment Risks
- Operating margin of -11.5% and net loss of -$598M demonstrate fundamental unprofitability requiring urgent operational restructuring
- Negative interest coverage ratio of -23.4x means company cannot service debt obligations from operating income, creating refinancing risk
- Revenue decline of 3% combined with high fixed cost structure indicates shrinking business with insufficient operational leverage to restore profitability
Key Metrics to Watch
- Operating margin trend toward positive territory and evidence of cost restructuring success
- Revenue stabilization and return to growth to improve leverage metrics
- Interest coverage ratio and debt reduction progress given $2.3B long-term debt burden
DENTSPLY SIRONA Inc. (XRAY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 2.8% FCF margin may limit capital allocation flexibility.
XRAY Profit Margin, ROE & Profitability Analysis
XRAY vs Healthcare Sector: How DENTSPLY SIRONA Inc. Compares
How DENTSPLY SIRONA Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DENTSPLY SIRONA Inc. Stock Overvalued? XRAY Valuation Analysis 2026
Based on fundamental analysis, DENTSPLY SIRONA Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DENTSPLY SIRONA Inc. Balance Sheet: XRAY Debt, Cash & Liquidity
XRAY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: DENTSPLY SIRONA Inc.'s revenue has remained relatively flat over the 5-year period, with a 7% decline. The most recent EPS of $-0.62 indicates the company is currently unprofitable.
XRAY Revenue Growth, EPS Growth & YoY Performance
XRAY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $904.0M | -$427.0M | $-2.14 |
| Q2 2025 | $936.0M | -$4.0M | $-0.02 |
| Q1 2025 | $879.0M | $18.0M | $0.09 |
| Q3 2024 | $947.0M | -$199.0M | $-0.94 |
| Q2 2024 | $984.0M | -$4.0M | $-0.02 |
| Q1 2024 | $953.0M | $18.0M | $-0.09 |
| Q3 2023 | $947.0M | -$199.0M | $-0.94 |
| Q2 2023 | $1.0B | $67.0M | $0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DENTSPLY SIRONA Inc. Dividends, Buybacks & Capital Allocation
XRAY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for DENTSPLY SIRONA Inc. (CIK: 0000818479)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XRAY
What is the AI rating for XRAY?
DENTSPLY SIRONA Inc. (XRAY) has an AI rating of SELL with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XRAY's key strengths?
Claude: Healthy gross margin of 50% indicates pricing power and manufacturing efficiency in core business. Positive operating cash flow of $235M despite net losses suggests cash generation capability and working capital management.
What are the risks of investing in XRAY?
Claude: Operating margin of -11.5% and net loss of -$598M demonstrate fundamental unprofitability requiring urgent operational restructuring. Negative interest coverage ratio of -23.4x means company cannot service debt obligations from operating income, creating refinancing risk.
What is XRAY's revenue and growth?
DENTSPLY SIRONA Inc. reported revenue of $3.7B.
Does XRAY pay dividends?
DENTSPLY SIRONA Inc. pays dividends, with $128.0M distributed to shareholders in the trailing twelve months.
Where can I find XRAY SEC filings?
Official SEC filings for DENTSPLY SIRONA Inc. (CIK: 0000818479) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XRAY's EPS?
DENTSPLY SIRONA Inc. has a diluted EPS of $-3.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XRAY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, DENTSPLY SIRONA Inc. has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XRAY stock overvalued or undervalued?
Valuation metrics for XRAY: ROE of -44.7% (sector avg: 15%), net margin of -16.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XRAY stock in 2026?
Our dual AI analysis gives DENTSPLY SIRONA Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XRAY's free cash flow?
DENTSPLY SIRONA Inc.'s operating cash flow is $235.0M, with capital expenditures of $131.0M. FCF margin is 2.8%.
How does XRAY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -16.3% (avg: 12%), ROE -44.7% (avg: 15%), current ratio 1.51 (avg: 2).
Is DENTSPLY SIRONA Inc. carrying too much debt?
XRAY has a debt-to-equity ratio of 1.70x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.51 suggests adequate short-term liquidity.